Research snapshot: 2026-10-26T22:26:51Z UTC. Not financial advice. Not Mycelium allocations or partnerships.
How Mycelium fits
The Mycelium Strategy pairs $MYC liquidity with selected Solana projects so trading fees can fund growth. This write-up screens for possible additions using public filters only — proposals, not commitments.
Selection criteria
- On Solana.
- Circulating market cap below $1M at research time (CoinGecko named; DexScreener cross-check; FDV stated when no separate circulating figure).
- Working product people can use today.
- Not a meme-only token (playful branding OK if product is substantive).
- Trading for at least 60 days.
- At least $10,000 trading volume in the preceding 24 hours.
- At least $50,000 current DEX liquidity across verified pools, without double-counting the same pool.
- Product update, development activity, or substantive team communication within the preceding 30 days.
- Not already in the Mycelium Strategy (incl. KNOTS/PRCL/GABLE/KINS/DREAMS/GUAC/STREAM/ESF/JUBJUB).
- Not SOL / USDC / USDT / MYC / ESF.
Result: 3 qualifying picks + 1 near-miss (EKOS fails liquidity by ~$1.99k).
Sources for market figures: CoinGecko coin endpoints + DexScreener latest/dex/tokens/{mint} at 2026-10-26T22:26:51Z. Liquidity = sum of unique pairAddress USD liquidity where the mint is base or quote; 24h volume = sum of pools where the mint is the base token (avoids attributing quote-side noise).
Comparison (snapshot)
| AgenC | BioLLM | perpspad | EKOS (near-miss) | |
|---|---|---|---|---|
| Ticker | $AgenC | $BioLLM | $PERPSPAD | $EKOS |
| Mint | 5yC9…pump |
9oxG…pump |
PerPs…fHL |
Cwub…pump |
| Qualifies? | Yes | Yes | Yes | No — liq |
| Circ. mcap (CoinGecko) | $866,103 | $843,206 | $645,692 | $303,739 |
| DexScreener mcap (primary) | $879,119 | $850,928 | $642,878 | $303,775 |
| 24h vol (base pools) | ~$79.3k | ~$12.7k | ~$28.3k | ~$45.0k |
| DEX liq (unique) | ~$156.5k | ~$133.9k | ~$126.5k | ~$48.0k |
| Days trading | ~243 | ~237 | ~112 | ~71 |
| Top-10 ex-LP | ~54.5% | ~18.3% | ~24.9% | ~32.5% |
| Mint / freeze | revoked / revoked | revoked / revoked | revoked / revoked | revoked / revoked |
| Main LP lock | 100% | 100% | ~47% | ~99.8% |
| Rugcheck | score 3896 (holder warn) | score 1 | score 101 (mutable meta) | score 1 |
| Last activity | GitHub 2026-10-21; X 10-26 | Studio 10-05; X 10-26; mycelia API live-but-offline | X product 10-25/26 | GitHub 10-26 |
| Proposed MYC role | Collaboration (+ pair) | Liquidity pair | Pair + collaboration | (n/a — fails filter) |
| Main risk | ~39% single holder | Offline swarm / weak token link | Partial LP lock | Liq shortfall |
Analysis
The Mycelium Strategy is a Solana liquidity network: most tradable $MYC already sits in pools, and those pools’ fees fund the next connections. Partner slots currently include projects such as Knots, Parcl, Gable, Kintara, Daydreams, Guacamole, Streamflow and JubJub (verified via the public allocation API). This note looks for sub-$1M Solana names with a product someone can use today, enough volume and liquidity to matter in a pool, and recent shipping — then asks how each could sit beside $MYC without pretending any partnership already exists.
Three names cleared every filter at the 2026-10-26 ~22:27 UTC snapshot.
AgenC is an on-chain marketplace where AI agents take tasks and get paid on Solana. The public site streams live instructions — listings, moderation, attestor exits — with settlement in SOL. That is a working product, not a whitepaper. The token trades under $1M, with roughly $79k of 24-hour volume and about $156k of DEX liquidity, and the main PumpSwap LP is fully locked with mint and freeze authorities revoked. Development on the protocol repository continued through 21 October 2026, and the project account was active on X through 26 October. The honest caveat is ownership: after excluding LP vaults, the top ten wallets still hold around 54% of supply, and a single unlabeled wallet alone holds about 39%. Protocol fees are also SOL-native, so $AgenC’s link to product success is mostly social and coordination-based today. For Mycelium, the interesting proposal is collaboration first — letting agents escrow or price work in $MYC — with a MYC/AgenC pair as a secondary experiment. The trade-off is that a concentrated holder can whip any thin pair.
BioLLM builds software that bridges recorded neuron data, EEG, and robot control, shipping BioLLM Studio for desktop and an OpenAI-compatible Mycelia router. Studio’s latest release is dated 5 October 2026; the Mycelia /api/v1/models endpoint answered at research time but reported offline capacity (no_live_serving_node). Market structure is cleaner than AgenC’s: sub-$1M cap, ~$13k volume, ~$134k liquidity, 100% locked main LP, revoked authorities, and top-ten holders outside LP/system accounts near 18%. Recent X posts describe EEG-to-robot demos. The open question is token value: inference looks SOL-metered, and staking has been winding down, so $BioLLM is not yet a clear claim on product cash flows. A MYC/BioLLM liquidity pair is the most natural Mycelium role given the distributed float and locked LP; any Studio collaboration would be optional community tooling, not an existing deal. The watch item is whether Mycelia returns live serving capacity.
perpspad is a launchpad where each coin is backed by a live perp position and trading fees fund buybacks. The website is live; October posts show new AMZN pairing via Sunrise and recognition in Meteora’s builder spotlight. Numbers at snapshot: ~$646k CoinGecko mcap, ~$28k volume, ~$127k liquidity, 112 days of trading, revoked mint/freeze. Holder concentration after LP exclusion is moderate (~25%). The weaker safety details are a main-pool lock near 47% and mutable metadata on Rugcheck. Still, the product is a fee engine in the same family of ideas as Mycelium’s pool-fee loop, which makes a MYC pair and optional MYC-backed launches plausible proposals — again, proposals only.
EKOS came closest without qualifying. It is an open-source Rust knowledge compiler for agents, with same-day GitHub commits and locked LP, but DexScreener liquidity summed to about $48k — roughly $2k under the $50k floor. Quality of product is not the issue; the filter is.
None of these are approved Mycelium allocations. They are research candidates that met (or nearly met) a strict public checklist. Facts above are point-in-time; volumes and liquidity move. No returns are guaranteed.
Discuss these findings and the Mycelium Strategy: https://discord.gg/5M7FsQcGq
Top comments (0)